IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 265 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.49 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,732,000 | -13.2% | 389,588 | 0.0% | 0.66% | -33.3% |
| Q2 2022 | $4,301,000 | -33.7% | 389,588 | 0.0% | 0.98% | -35.9% |
| Q1 2022 | $6,487,000 | -12.8% | 389,588 | 0.0% | 1.53% | -37.4% |
| Q4 2021 | $7,437,000 | -22.6% | 389,588 | 0.0% | 2.45% | -29.8% |
| Q3 2021 | $9,607,000 | -27.0% | 389,588 | -23.0% | 3.49% | -35.4% |
| Q2 2021 | $13,163,000 | -26.5% | 505,890 | -10.6% | 5.41% | -28.3% |
| Q1 2021 | $17,916,000 | -31.8% | 565,890 | 0.0% | 7.55% | -19.6% |
| Q4 2020 | $26,257,000 | +33.6% | 565,890 | -5.2% | 9.39% | +12.8% |
| Q3 2020 | $19,650,000 | +18.5% | 596,890 | -1.2% | 8.32% | +12.6% |
| Q2 2020 | $16,577,000 | +12.7% | 603,890 | +22.9% | 7.39% | -17.1% |
| Q1 2020 | $14,710,000 | +17.1% | 491,390 | +8.3% | 8.92% | +17.2% |
| Q4 2019 | $12,564,000 | – | 453,890 | – | 7.62% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
| Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
| GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
| FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
| Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
| Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
| QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
| Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
| Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
| EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |